Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial

PLoS Med. 2013;10(4):e1001426. doi: 10.1371/journal.pmed.1001426. Epub 2013 Apr 16.

Abstract

Background: Preliminary evidence suggests a nephroprotective effect of urinary alkalinization in patients at risk of acute kidney injury. In this study, we tested whether prophylactic bicarbonate-based infusion reduces the incidence of acute kidney injury and tubular damage in patients undergoing open heart surgery.

Methods and findings: In a multicenter, double-blinded (patients, clinical and research personnel), randomized controlled trial we enrolled 350 adult patients undergoing open heart surgery with the use of cardiopulmonary bypass. At induction of anesthesia, patients received either 24 hours of intravenous infusion of sodium bicarbonate (5.1 mmol/kg) or sodium chloride (5.1 mmol/kg). The primary endpoint was the proportion of patients developing acute kidney injury. Secondary endpoints included the magnitude of acute tubular damage as measured by urinary neutrophil gelatinase-associated lipocalin (NGAL), initiation of acute renal replacement therapy, and mortality. The study was stopped early under recommendation of the Data Safety and Monitoring Committee because interim analysis suggested likely lack of efficacy and possible harm. Groups were non-significantly different at baseline except that a greater proportion of patients in the sodium bicarbonate group (66/174 [38%]) presented with preoperative chronic kidney disease compared to control (44/176 [25%]; p = 0.009). Sodium bicarbonate increased urinary pH (from 6.0 to 7.5, p<0.001). More patients receiving bicarbonate (83/174 [47.7%]) developed acute kidney injury compared with control patients (64/176 [36.4%], odds ratio [OR] 1.60 [95% CI 1.04-2.45]; unadjusted p = 0.032). After multivariable adjustment, a non-significant unfavorable group difference affecting patients receiving sodium bicarbonate was found for the primary endpoint (OR 1.45 [0.90-2.33], p = 0.120]). A greater postoperative increase in urinary NGAL in patients receiving bicarbonate infusion was observed compared to control patients (p = 0.011). The incidence of postoperative renal replacement therapy was similar but hospital mortality was increased in patients receiving sodium bicarbonate compared with control (11/174 [6.3%] versus 3/176 [1.7%], OR 3.89 [1.07-14.2], p = 0.031).

Conclusions: Urinary alkalinization using sodium bicarbonate infusion was not found to reduce the incidence of acute kidney injury or attenuate tubular damage following open heart surgery; however, it was associated with a possible increase in mortality. On the basis of these findings we do not recommend the prophylactic use of sodium bicarbonate infusion to reduce the risk of acute kidney injury. Discontinuation of growing implementation of this therapy in this setting seems to be justified.

Trial registration: ClinicalTrials.gov NCT00672334 Please see later in the article for the Editors' Summary.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / mortality
  • Acute Kidney Injury / prevention & control*
  • Acute-Phase Proteins / urine
  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiopulmonary Bypass
  • Double-Blind Method
  • Female
  • Hospital Mortality
  • Humans
  • Hydrogen-Ion Concentration
  • Kidney / drug effects*
  • Kidney / pathology
  • Kidney Tubules / drug effects
  • Kidney Tubules / pathology
  • Lipocalin-2
  • Lipocalins / urine
  • Male
  • Middle Aged
  • Postoperative Complications / mortality
  • Postoperative Complications / prevention & control*
  • Postoperative Complications / surgery
  • Proto-Oncogene Proteins / urine
  • Renal Insufficiency, Chronic / complications
  • Renal Replacement Therapy
  • Sodium Bicarbonate* / adverse effects
  • Sodium Bicarbonate* / therapeutic use
  • Thoracic Surgery* / methods
  • Treatment Failure
  • Urinalysis

Substances

  • Acute-Phase Proteins
  • LCN2 protein, human
  • Lipocalin-2
  • Lipocalins
  • Proto-Oncogene Proteins
  • Sodium Bicarbonate

Associated data

  • ClinicalTrials.gov/NCT00672334

Grants and funding

This study was funded by grants from the German Heart Foundation (Deutsche Stiftung für Herzforschung, Frankfurt a. M., Germany), the Else Kröner-Fresenius-Stiftung (Bad Homburg, Germany), the Canadian Intensive Care Foundation (Edmonton, Canada), the Intensive Care Foundation (Melbourne, Australia), and the Austin Hospital ICU Research Fund (Melbourne, Australia). SMB is supported by a Canada Research Chair in Critical Care Nephrology and a Clinician Scientist Award from Alberta Innovates – Health Solutions (AI-HS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.